Aprea Therapeutics Inc (APRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aprea Therapeutics Inc (APRE) has a cash flow conversion efficiency ratio of -0.064x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.76 Million) by net assets ($42.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Aprea Therapeutics Inc (APRE) market capitalisation for the company's overall valuation and market capitalisation.
Aprea Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Aprea Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aprea Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aprea Therapeutics Inc ranked by their cash flow conversion efficiency. See APRE debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daesang Holdings Co Ltd Pref
KO:084695
|
-0.041x |
|
ECP Emerging Growth Ltd
AU:ECP
|
-0.023x |
|
Together Startup Network Ltd
TA:TGTR
|
-0.149x |
|
Curanex Pharmaceuticals Inc Common Stock
NASDAQ:CURX
|
-0.643x |
|
Noida Toll Bridge Company Limited
NSE:NOIDATOLL
|
-1.598x |
|
Nyrstar NV
BR:NYR
|
0.000x |
|
Mason Graphite Inc.
V:LLG
|
-0.007x |
|
Alkali Metals Limited
NSE:ALKALI
|
0.040x |
Annual Cash Flow Conversion Efficiency for Aprea Therapeutics Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Aprea Therapeutics Inc from 2007 to 2025. View APRE stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $12.44 Million | $-12.89 Million | -1.036x | -47.60% |
| 2024-12-31 | $19.31 Million | $-13.56 Million | -0.702x | -5.31% |
| 2023-12-31 | $18.26 Million | $-12.18 Million | -0.667x | +31.64% |
| 2022-12-31 | $25.64 Million | $-25.01 Million | -0.975x | -28.13% |
| 2021-12-31 | $49.51 Million | $-37.69 Million | -0.761x | -40.94% |
| 2020-12-31 | $77.40 Million | $-41.80 Million | -0.540x | -151.25% |
| 2019-12-31 | $124.24 Million | $-26.71 Million | -0.215x | -172.51% |
| 2018-12-31 | $-51.44 Million | $-15.25 Million | 0.296x | -24.27% |
| 2017-12-31 | $-35.77 Million | $-14.00 Million | 0.392x | -56.40% |
| 2007-12-31 | $-2.11 Million | $-1.90 Million | 0.898x | -- |
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tum… Read more